QUICK ANSWER · AEO / GEO
An ACTH-fragment-related neuropeptide with country-specific product history; this is not equivalent to global approval.
ENTITY FACTS
What should readers identify first?
What remains unknown?
- whether study material was free base, acetate or another semax-related form
- robust efficacy from adequately powered, blinded, randomized trials with patient-important outcomes
- human pharmacokinetics and route/formulation comparability
- long-term immunogenicity, carcinogenicity, reproductive and developmental safety
- clinical significance of BDNF and resting-state fMRI changes
- future Russian/EAEU registration, label or presentation changes after the 2025 product renewals
- current Thailand, EU and UK marketing-authorisation status pending direct local verification
What limits these conclusions?
- The human literature includes small imaging studies, meeting abstracts, Russian-language reports, uncontrolled studies and concomitant therapies. FDA could not determine whether clinical-study material was free base or a salt, found no human pharmacokinetic studies and judged the effectiveness evidence insufficient for cerebral ischemia, migraine and trigeminal neuralgia. Russian registration does not resolve these evidence limitations or create approval elsewhere.
This overview does not replace the detailed adverse-event and product-specific risk discussion in the complete Thai profile or the original sources.
EVIDENCE BOUNDARY
What this overview does not establish
- An evidence grade does not rank this molecule against another treatment.
- A molecule name does not establish the identity, purity or regulatory status of a product.
- Animal, cell or biomarker findings do not automatically establish human clinical benefit.
- Approval in one country or indication does not transfer globally.
Where can I check the evidence?
Original sources from the same evidence record used by Compare. Read each source's population, methods, limitations and date; a citation is not product endorsement.
- https://www.fda.gov/media/193348/download
- https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026
- https://www.lsgeotar.ru/drugs/semax-BAZ7
- https://files.dev.lsgeotar.ru/public/4oK6BsG8RZ0KmNXJaX969w.pdf
- https://pubmed.ncbi.nlm.nih.gov/29798983/
- https://pubmed.ncbi.nlm.nih.gov/30225715/
- https://pubmed.ncbi.nlm.nih.gov/32342318/
- https://pubmed.ncbi.nlm.nih.gov/17603664/
- https://www.wada-ama.org/en/resources/world-anti-doping-program/prohibited-list
- https://products.mhra.gov.uk/
FAQ · ANSWER ENGINE
Frequently asked questions
What is Semax?
Semax is described pharmacologically as Synthetic ACTH(4-10)-related heptapeptide without established corticotropic activity. An ACTH-fragment-related neuropeptide with country-specific product history; this is not equivalent to global approval.
Does Semax have strong evidence?
PrimeCoreBio records Evidence Grade C. This grade describes evidence strength, not comparative effectiveness or suitability for an individual.
Is Semax approved everywhere?
No global conclusion should be inferred. PrimeCore Class A must be read with the exact product, country and indication on the source-rich profile.
Educational information only. This page does not provide diagnosis, treatment, prescribing, dosage, injection instructions or individual medical advice.